These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38548178)

  • 1. Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.
    Gregorio C; Rea F; Ieva F; Scagnetto A; Indennidate C; Cappelletto C; Di Lenarda A; Barbati G
    Value Health; 2024 Jul; 27(7):897-906. PubMed ID: 38548178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.
    Dressel A; Schmidt B; Schmidt N; Laufs U; Fath F; Chapman MJ; Grammer TB; März W
    Vascul Pharmacol; 2019 Sep; 120():106566. PubMed ID: 31207358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
    Kumar R; Tonkin A; Liew D; Zomer E
    Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.
    Landmesser U; Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
    Eur Heart J Qual Care Clin Outcomes; 2022 Jan; 8(1):31-38. PubMed ID: 33063111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review.
    Azari S; Rezapour A; Omidi N; Alipour V; Behzadifar M; Safari H; Tajdini M; Bragazzi NL
    Heart Fail Rev; 2020 Nov; 25(6):1077-1088. PubMed ID: 31832834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.
    Liang Z; Chen Q; Yang F; Yan X; Zhang X; Chen X; Fang F; Zhao Q
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):775-785. PubMed ID: 33090294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world lipid lowering effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: A single-centre study.
    Han J; Bilgrami S; Ross S; Broadhead H; Attar N
    Int J Cardiol; 2021 Jan; 322():240-244. PubMed ID: 32827563
    [No Abstract]   [Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
    Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
    Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
    Macchi C; Ferri N; Favero C; Cantone L; Vigna L; Pesatori AC; Lupo MG; Sirtori CR; Corsini A; Bollati V; Ruscica M
    Eur J Prev Cardiol; 2019 Apr; 26(6):578-588. PubMed ID: 30477320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Inhibitors Show Value for Patients and the US Health Care System.
    Cheng WH; Gaudette É; Goldman DP
    Value Health; 2017 Dec; 20(10):1270-1278. PubMed ID: 29241886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.
    Marquina C; Zomer E; Vargas-Torres S; Zoungas S; Ofori-Asenso R; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Oct; 38(10):1095-1113. PubMed ID: 32583316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR; Beavers CJ
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.
    Arrieta A; Page TF; Veledar E; Nasir K
    PLoS One; 2017; 12(1):e0169761. PubMed ID: 28081164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
    Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies.
    Bagepally BS; Sasidharan A
    Eur J Clin Pharmacol; 2022 Mar; 78(3):351-363. PubMed ID: 34708270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.